Laboratory of Membrane and Liposome Research, IMRIC, The Hebrew University-Hadassah Medical School , Jerusalem 91120, Israel.
Institute of Protein Biochemistry, National Research Council , 80131 Napoli, Italy.
ACS Nano. 2017 Jan 24;11(1):12-18. doi: 10.1021/acsnano.6b08244. Epub 2017 Jan 9.
Remarkable progress has recently been made in the synthesis and characterization of engineered nanoparticles for imaging and treatment of cancers, resulting in several promising candidates in clinical trials. Despite these advances, clinical applications of nanoparticle-based therapeutic/imaging agents remain limited by biological, immunological, and translational barriers. In order to overcome the existing status quo in drug delivery, there is a need for open and frank discussion in the nanomedicine community on what is needed to make qualitative leaps toward translation. In this Nano Focus, we present the main discussion topics and conclusions from a recent workshop: "Mechanisms and Barriers in Nanomedicine". The focus of this informal meeting was on biological, toxicological, immunological, and translational aspects of nanomedicine and approaches to move the field forward productively. We believe that these topics reflect the most important issues in cancer nanomedicine.
在癌症成像和治疗的工程纳米粒子的合成和特性研究方面最近取得了显著进展，这导致了一些有前途的候选药物正在临床试验中。尽管取得了这些进展，但基于纳米粒子的治疗/成像剂的临床应用仍然受到生物学、免疫学和转化障碍的限制。为了克服药物输送方面的现状，纳米医学领域需要就实现向质的飞跃所需的条件进行公开和坦诚的讨论。在这个 Nano Focus 中，我们展示了最近一次研讨会“纳米医学中的机制和障碍”的主要讨论话题和结论。这次非正式会议的重点是纳米医学的生物学、毒理学、免疫学和转化方面，以及推动该领域向前发展的方法。我们相信这些话题反映了癌症纳米医学中最重要的问题。
